JNCEUnknown
Jounce Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Jounce Therapeutics, Inc. (JNCE), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are JNCE insiders buying or selling?
Jounce Therapeutics, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since January 2018, Trabud has recorded 50 Form 4 filings for JNCE: 2 buys ($100.9K) and 48 sells ($42.4M).
Source: SEC EDGAR Form 4
Key Statistics (January 2018 – Apr 6, 2023)
Total Form 4 filings
50
SEC EDGAR
Insider filers
9
Insider buys (2)
$100.9K
Insider sells (48)
$42.4M
Insider sentiment
Net sellingNet insider flow of $42.3M in net selling since January 2018.
Recent JNCE insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Apr 6, 2023 | Richard /Ca/ Murray | Director | Sale | 39.2K | $1.85 | $72.6K | SEC ↗ |
| Mar 15, 2023 | Kevin C Tang | 10% Owner | Purchase | 86.0K | $1.00 | $86.0K | SEC ↗ |
| Jan 12, 2023 | Elizabeth Trehu | Chief Medical Officer | Sale | 9.3K | $1.11 | $10.3K | SEC ↗ |
| Jan 12, 2023 | Richard /Ca/ Murray | CEO and President | Sale | 45.1K | $1.11 | $50.1K | SEC ↗ |
| Jan 12, 2023 | Kimberlee C Drapkin | CFO and Treasurer | Sale | 14.1K | $1.11 | $15.7K | SEC ↗ |
| Jan 12, 2023 | Hugh M Cole | Chief Operating Officer | Sale | 16.6K | $1.11 | $18.5K | SEC ↗ |
| Jan 12, 2022 | Elizabeth Trehu | Chief Medical Officer | Sale | 8.4K | $6.88 | $57.7K | SEC ↗ |
| Jan 12, 2022 | Richard /Ca/ Murray | CEO and President | Sale | 37.3K | $6.88 | $256.7K | SEC ↗ |
| Nov 17, 2021 | Kevin P Starr | 10% Owner | Sale | 1.9M | $8.38 | $15.9M | SEC ↗ |
| May 27, 2021 | Kevin P Starr | 10% Owner | Sale | 552.5K | $8.00 | $4.4M | SEC ↗ |
| Apr 17, 2021 | John Duncan Higgons | Director | Sale | 200 | $10.00 | $2.0K | SEC ↗ |
| Apr 1, 2021 | Elizabeth Trehu | Chief Medical Officer | Sale | 13.5K | $10.09 | $136.2K | SEC ↗ |
| Mar 18, 2021 | John Duncan Higgons | Director | Sale | 200 | $12.80 | $2.6K | SEC ↗ |
| Mar 3, 2021 | Kevin P Starr | 10% Owner | Sale | 1.4M | $11.75 | $17.0M | SEC ↗ |
| Feb 19, 2021 | John Duncan Higgons | Director | Sale | 200 | $11.78 | $2.4K | SEC ↗ |
| Jan 25, 2021 | Richard /Ca/ Murray | CEO and President | Sale | 33.5K | $12.06 | $404.2K | SEC ↗ |
| Jan 25, 2021 | Hugh M Cole | Chief Business Officer | Sale | 18.0K | $11.95 | $215.1K | SEC ↗ |
| Jan 22, 2021 | Elizabeth Trehu | Chief Medical Officer | Sale | 6.5K | $12.01 | $78.1K | SEC ↗ |
| Jan 22, 2021 | John Duncan Higgons | Director | Sale | 1.7K | $11.90 | $20.2K | SEC ↗ |
| Jan 22, 2021 | Kimberlee C Drapkin | CFO and Treasurer | Sale | 30.0K | $11.36 | $340.8K | SEC ↗ |
| Jan 21, 2021 | Richard /Ca/ Murray | CEO and President | Sale | 86.5K | $9.69 | $838.2K | SEC ↗ |
| Jan 11, 2021 | Elizabeth Trehu | Chief Medical Officer | Sale | 5.3K | $6.89 | $36.5K | SEC ↗ |
| Jan 11, 2021 | Richard /Ca/ Murray | CEO and President | Sale | 22.0K | $6.89 | $151.5K | SEC ↗ |
| Jan 11, 2021 | Kimberlee C Drapkin | CFO and Treasurer | Sale | 5.8K | $6.89 | $40.1K | SEC ↗ |
| Jan 11, 2021 | Hugh M Cole | Chief Business Officer | Sale | 6.2K | $6.89 | $42.8K | SEC ↗ |
Showing the 25 most recent of 50 Form 4 filings for Jounce Therapeutics, Inc..
Most active JNCE insiders
- Elizabeth Trehu10 filings
- Richard /Ca/ Murray10 filings
- Kimberlee C Drapkin9 filings
- Hugh M Cole7 filings
- John Duncan Higgons5 filings
Ask anything about JNCE insider activity
Use Trabud's AI agent to query Jounce Therapeutics, Inc.'s Form 4 history in plain English — "Show me JNCE CEO purchases this year" or compare it against any other ticker.
Open the AI agentJNCE insider trading FAQ
Are Jounce Therapeutics, Inc. insiders buying or selling?
Jounce Therapeutics, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since January 2018, Trabud has recorded 50 Form 4 filings for JNCE: 2 buys ($100.9K) and 48 sells ($42.4M). Over the full record that is net selling of $42.3M.
How many insiders trade JNCE stock?
9 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Jounce Therapeutics, Inc.. The most recent filing was accepted on Apr 6, 2023.
Where does Trabud get JNCE insider trading data?
All JNCE insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.